Literature DB >> 35932031

Absence of a weekday effect on short- and long-term oncologic outcomes of gastrectomy for gastric cancer: a propensity score matching analysis.

Tsuneyuki Uchida1, Ryuichi Sekine2, Kenichi Matsuo2, Gaku Kigawa2, Takahiro Umemoto2, Mikio Makuuchi2,3, Kuniya Tanaka2.   

Abstract

BACKGROUND: Day of the week when elective gastrointestinal surgery is performed may be influenced by various background and tumor-related factors. Relationships between postoperative outcome and when in the week gastrectomy is performed remain controversial. We undertook this study to evaluate whether weekday of gastrectomy influenced outcomes of gastric cancer treatment ("weekday effect").
METHODS: Patients who underwent curative surgery for gastric cancer between 2004 and 2017 were included in this retrospective study. To obtain 2 cohorts well balanced for variables that might influence clinical outcomes, patients whose gastrectomy was performed early in the week (EW group) were matched 1:1 with others undergoing gastrectomy later in the week (LW group) by use of propensity scores.
RESULTS: Among 554 patients, 216 were selected from each group by propensity score matching. Incidence of postoperative complications classified as Clavien-Dindo grade II or higher was similar between EW and LW groups (20.4% vs. 24.1%; P = 0.418). Five-year overall and recurrence-free survival were 86.0% and 81.9% in the EW group, and 86.2% and 81.1% in the LW group (P = 0.981 and P = 0.835, respectively).
CONCLUSIONS: Short- and long-term outcomes were comparable between gastric cancer patients who underwent gastrectomy early and late in the week.
© 2022. The Author(s).

Entities:  

Keywords:  Gastrectomy; Gastric cancer; Prognosis; Propensity score matching; Weekday effect

Mesh:

Year:  2022        PMID: 35932031      PMCID: PMC9356429          DOI: 10.1186/s12893-022-01756-z

Source DB:  PubMed          Journal:  BMC Surg        ISSN: 1471-2482            Impact factor:   2.030


Background

Gastrectomy is the mainstay of curative treatment for patients with gastric cancer [1]. Combining surgery with chemotherapy and multi-modal treatment has increased survival of patients with resectable gastric cancer [1, 2]. However, overall 5-year postoperative survival is only about 70%, and is strongly dependent on tumor stage at time of surgery: better than 70% for stages I and II, 35% to 54% for stage III, and less than 20% for stage IV [3]. Therefore, we need to identify additional modifiable factors that can improve postoperative prognosis. Two large studies [4, 5] have associated performance of surgery for gastrointestinal cancer late in the week with greater mortality within 30 postoperative days, attributing this weekday effect to fatigue among surgeons over the course of the week that might impact details of the operation and extent of dissection. These reports also suggested increased risk of tumor recurrence. In contrast, other studies concluded that any weekday effect observed did not alter postoperative prognosis [6, 7], so the relationship between day of surgery and clinical results remains controversial. To our best knowledge, no analyses of this issue in gastric cancer have made adjustments for background factors using propensity score matching. In the present study we used propensity score matching analysis to minimize distortion from differing patient characteristics with the aim of determining whether late weekday gastrectomy increases postoperative complications or worsens prognosis in patients with gastric cancer.

Methods

Study population

Between January 2004 and December 2017, elective gastrectomy to treat primary gastric cancer was performed for 699 consecutive patients at the Department of Gastroenterological and General Surgery of Showa University Fujigaoka Hospital. The study population consisted of single-race patients (Japanese). All elective gastrectomies were performed between Monday and Friday. Among these patients, 145 were excluded from the study for the following reasons: preoperative chemotherapy administration in 61 patients; limited gastric resection in 5; palliative gastrectomy defined as R1 or R2 resection [8] in 25; clinical stage IV in 11; pathologic stage IV in 41; and insufficient data for analysis in 2. For the remaining 554 patients, clinical and pathologic data were collected from medical records for retrospective analysis (Fig. 1). Pulmonary function parameters such as vital capacity (VC), %VC, forced expiratory volume (FEV) 1.0, and FEV1.0%, were measured by spirometry. We defined ventilatory impairment as restrictive or obstructive as follows: restrictive ventilatory impairment was %VC below 80% of that predicted, while obstructive ventilatory impairment was FEV1.0% below 70% of forced VC. Data collection and analysis were approved by the institutional review board of Showa University Fujigaoka Hospital (Approval No. F2020C74). All patients provided informed consent for use of anonymous data through an opt-out methodology.
Fig. 1

Flow chart of study including patient selection and group assignment

Flow chart of study including patient selection and group assignment Extent of lymph node dissection was described in accordance with the 2014 Japanese Gastric Cancer Treatment Guidelines (version 4), and cancer staging was based on the 8th edition of the Union for International Cancer Control (UICC) TNM classification system [8, 9]. Analysis was performed for a dichotomized weekday model: Monday and Tuesday were defined as early weekday (EW), while Wednesday through Friday were late weekday (LW), based upon the division of the week used in previous studies of surgical outcome according to when in the week surgery was performed [5, 6]. To confirm similarity of surgical outcomes for the beginning and end of the 5-day work week, a subgroup analysis comparing Monday and Friday surgery was added.

Postoperative complications

Postoperative complications occurring within 30 days after gastrectomy and assigned a Clavien-Dindo classification of Grade II or higher were reviewed retrospectively [10]. If multiple complications occurred in a single patient, the complication with the highest grade was used for analysis.

Follow-up and definition of recurrence

Physical examination and blood testing, including tumor markers, were performed every 3 months. Patients underwent at least one type of imaging, usually computed tomography, at 6-month intervals during the first 2 years after surgery and then at 1-year intervals until 5 years after surgery [8]. Recurrence was diagnosed on the basis of findings of radiologic and/or cytologic studies. Even when tumor markers in the blood exceeded normal limits, no diagnosis of recurrence was made before radiologic and/or cytologic evidence had been reviewed. Follow-up data extended to September 2021.

Propensity score matching

We used propensity score matching to attain optimal balance among baseline variables between EW and LW groups and also between Monday and Friday groups. Propensity scores were estimated using a logistic regression model based on the following 12 variables: age, gender, body mass index (BMI), diabetes mellitus, chronic obstructive pulmonary disease (COPD), serum albumin, carcinoembryonic antigen (CEA), carbohydrate antigen (CA)19-9, impairment of respiratory function, operative procedure, lymph node dissection, and pathologic TNM stage. One-to-one matching without replacement was performed using a 0.2 caliper width, and the resulting score-matched pairs were used in subsequent analyses.

Statistical analysis

Baseline data are presented as medians with interquartile ranges for continuous variables and as numbers with percentages for categorical variables. The Mann–Whitney U test was used to compare continuous variables, while Fisher’s exact test was used to compare categorical variables. Overall survival (OS) was defined as the interval from date of gastrectomy to date of death from any cause. Relapse-free survival (RFS) was defined as the interval from the date of gastrectomy to the date of recurrence of gastric cancer or the date of death from any cause. Surviving patients were censored at the date that they were last known to be alive. Survival was displayed on Kaplan–Meier curves and compared using the log-rank test. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using the Cox proportional hazards model. P values below 0.05 were considered to indicate statistical significance. Statistical analysis was conducted using JMP Pro version 15.0 (SAS Institute, Cary, NC, USA).

Results

Patient demographics

In this study 554 patients were enrolled, including 377 men and 177 women with a median age of 70 years. Among all patients, 233 (42.1%) had gastrectomy on Monday, 6 (1.1%) on Tuesday, 110 (19.8%) on Wednesday, 1 (0.2%) on Thursday, and 204 (36.8%) on Friday. Characteristics of the 554 study participants comprising the EW group (n = 239) and the LW group (n = 315) are presented in Table 1. Patients in the LW group had a lower serum albumin concentration (P = 0.021) than those in the EW group. After propensity score matching for weekday of gastrectomy, 216 matched pairs were selected (Fig. 1). After matching, characteristics of patients were conserved and no statistically significant differences in characteristics were present between the EW and LW groups (Table 1).
Table 1

Comparison of early and late weekday groups (EW and LW) before and after propensity score matching

All patients (n = 554)P valuePropensity score-matched patients (n = 432)P value
EW group (n = 239)LW group (n = 315)EW group (n = 216)LW group (n = 216)
Age, years (median, IQR)70 (62–77)70 (63–77)0.71770 (62–77)69 (62–77)0.889
Gender (n, %)0.5210.760
 Male159 (66.5%)218 (69.2%)145 (67.1%)141 (65.3%)
 Female80 (33.5%)97 (30.8%)71 (32.9%)75 (34.7%)
Time period (n, %)0.1030.101
 2004–2010104 (43.5%)160 (50.8%)91 (42.1%)109 (50.5%)
 2011–2017135 (56.5%)155 (49.2%)125 (57.9%)107 (49.5%)
BMI, kg/m2 (median, IQR)22.7 (20.9–24.5)22.5 (20.3–24.4)0.16122.8 (20.9–24.5)22.7 (20.7–24.9)0.806
Diabetes mellitus (n, %)1.000
 Absent202 (84.5%)267 (84.8%)182 (84.3%)182 (84.3%)1.000
 Present37 (15.5%)48 (15.2%)34 (15.7%)34 (15.7%)
COPD (n, %)0.7191.000
 Absent226 (94.6%)295 (93.7%)203 (94.0%)202 (93.5%)
 Present13 (5.4%)20 (6.3%)13 (6.0%)14 (6.5%)
Hemoglobin, g/dl (median, IQR)12.7 (11.7–13.9)12.7 (11.1–13.7)0.16712.7 (11.7–13.9)12.8 (11.6–13.9)0.803
Albumin, g/dl (median, IQR)4.1 (3.9–4.4)4.0 (3.7–4.3)0.0214.1 (3.9–4.4)4.1 (3.8–4.4)0.750
CEA, ng/ml (median, IQR)1.6 (0.9–2.6)1.6 (1.0–2.5)0.8341.6 (0.9–2.6)1.6 (0.9–2.5)0.983
CA19-9, U/ml (median, IQR)9.4 (6.0–15.6)10 (6.8–17.3)0.1619.6 (6.4–15.8)10 (6.5–17.0)0.371
Impairment of respiratory function (n, %)0.2711.000
 Absent156 (65.3%)220 (69.8%)141 (65.3%)140 (64.8%)
 Present83 (34.7%)95 (30.2%)75 (34.7%)76 (35.2%)
Clinical tumor depth (n, %)0.3990.881
 cT1127 (53.1)154 (48.9)116 (53.7%)121 (56.0%)
 cT254 (22.6)65 (20.6)49 (22.7%)47 (21.8%)
 cT335 (14.6)53 (16.8)34 (15.7%)29 (13.4%)
 cT423 (9.6)43 (13.7)17 (7.9%)19 (8.8%)
Clinical lymph node metastasis (n, %)0.0560.545
 cN0187 (78.2%)215 (68.3%)172 (80.0%)160 (74.1%)
 cN140 (16.7%)72 (22.9%)34 (15.7%)44 (20.4%)
 cN211 (4.6%)25 (7.9%)9 (4.2%)10 (4.6%)
 cN31 (0.4%)3 (1.0%)1 (0.5%)2 (0.9%)
Clinical TNM stage (n, %)0.0750.180
 I165 (69.0%)193 (61.3%)150 (69.4%)149 (69.0%)
 IIA16 (6.7%)26 (8.3%)15 (6.9%)19 (8.8%)
 IIB22 (9.2%)22 (7.0%)22 (10.2%)11 (5.1%)
 III36 (15.1%)73 (23.2%)29 (13.4%)36 (16.7%)
 IVA01 (0.3%)01 (0.5%)
Operative procedure (n, %)0.4480.915
 Distal gastrectomy168 (70.3%)222 (70.5%)155 (71.8%)153 (70.8%)
 Proximal gastrectomy3 (1.3%)1 (0.3%)00
 Total gastrectomy68 (28.4%)92 (29.2%)61 (28.2%)63 (29.2%)
Operative approach (n, %)0.0590.176
 Open107 (44.8%)167 (53.0%)91 (42.1%)106 (49.1%)
 Laparoscopic132 (55.2%)148 (47.0%)125 (57.9%)110 (50.9%)
Lymph node dissection (n, %)0.2301.000
 D1/D1+127 (53.1%)150 (47.6%)117 (54.2%)116 (53.7%)
 D2 or more112 (46.9%)165 (52.4%)99 (45.8%)100 (46.3%)

BMI body mass index, COPD chronic obstructive pulmonary disease, IQR interquartile range, CEA carcinoembryonic antigen, CA carbohydrate antigen

Comparison of early and late weekday groups (EW and LW) before and after propensity score matching BMI body mass index, COPD chronic obstructive pulmonary disease, IQR interquartile range, CEA carcinoembryonic antigen, CA carbohydrate antigen

Postoperative outcomes and pathologic findings

Among all patients, median operative time and blood loss were 345 min and 265 g, respectively. Operative time and blood loss did not differ between the two groups before or after propensity score matching. Before matching, patients in the LW group had more advanced depth of tumor invasion (P = 0.049) and lymph node metastasis (P = 0.018) than those in the EW group. After matching, all pathologic variables including depth of tumor invasion ceased to differ significantly among the groups (Table 2).
Table 2

Comparison of postoperative outcomes and pathologic findings between early and late weekday groups (EW and LW)

All patients (n = 554)P valuePropensity score-matched patients (n = 432)P value
EW group (n = 239)LW group (n = 315)EW group (n = 216)LW group (n = 216)
Operative time, minutes (median, IQR)350 (290–421)345 (277–420)0.530350 (290–420)341 (280–420)0.703
Operative blood loss, grams (median, IQR)202 (39–482)265 (45–645)0.095195 (30–460)230 (40–639)0.182
Blood transfusion (n, %)0.5810.499
 Not performed198 (82.9%)255 (80.9%)181 (83.8%)187 (86.6%)
 Performed41 (17.1%)60 (19.1%)35 (16.2%)29 (13.5%)
Hospital stay after surgery, days (median, IQR)13 (11–17)13 (11–18)0.4713 (10–17)13 (10–18)0.907
Death within 30 days after surgery (n, %)02 (0.6%)0.50802 (0.9%)0.499
In-hospital death (n, %)04 (1.3%)0.13702 (0.9%)0.499
Adjuvant chemotherapy (n, %)0.2110.788
 Absent204 (85.4%)255 (81.0%)182 (84.3%)185 (85.7%)
 Present35 (14.6%)60 (19.0%)34 (15.7%)31 (14.3%)
Tumor diameter, mm (median, IQR)35 (25–50)35 (22–60)0.31835 (25–50)34 (20–50)0.531
Retrieved number of lymph nodes (median, IQR)40 (27–50)38 (26–53)0.92239 (27–49)38 (25–53)0.930
Pathological tumor depth (n, %)0.0490.660
 pT1134 (56.1%)150 (47.6%)123 (56.9%)119 (55.1%)
 pT241 (17.1%)53 (16.8%)39 (18.1%)40 (18.5%)
 pT343 (18.0%)61 (19.4%)39 (18.1%)35 (16.2%)
 pT421 (8.8%)51 (16.2%)15 (6.9%)22 (10.2%)
Pathological lymph node metastasis (n, %)0.0180.844
 pN0173 (72.4%)204 (64.8%)156 (72.2%)161 (74.5%)
 pN129 (12.1%)49 (15.6%)29 (13.4%)24 (11.1%)
 pN210 (4.2%)33 (10.5%)10 (4.6%)12 (5.6%)
 pN327 (11.3%)29 (9.2%)21 (9.7%)19 (8.8%)
Pathological TNM stage (n, %)0.0750.992
 IA120 (50.2%)136 (43.2%)109 (50.5%)109 (50.5%)
 IB42 (17.6%)47 (14.9%)40 (18.5%)41 (19.0%)
 IIA24 (10.0%)35 (11.1%)23 (10.7%)24 (11.1%)
 IIB19 (8.0%)33 (10.5%)16 (7.4%)12 (5.6%)
 IIIA8 (3.4%)37 (11.8%)8 (3.7%)10 (4.6%)
 IIIB20 (8.4%)17 (5.4%)15 (6.9%)15 (6.9%)
 IIIC6 (2.5%)10 (3.2%)5 (2.3%)5 (2.3%)

IQR interquartile range

Comparison of postoperative outcomes and pathologic findings between early and late weekday groups (EW and LW) IQR interquartile range Details of all complications are shown in Table 3. Considering all 554 patients, morbidity rates was 24.5% (136 patients). Before matching, although the total incidence of complications did not differ significantly among groups (20.5% in the EW group vs. 27.6% in the LW group, P = 0.059), the LW group had a greater incidence of pneumonia than the EW group (P = 0.006). After matching, total incidence of complications and details of individual complications did not differ significantly between groups.
Table 3

Comparison of postoperative complications between early and late weekday groups (EW and LW)

All patients (n = 554)P valuePropensity score-matched patients (n = 432)P value
EW group (n = 239)LW group (n = 315)EW group (n = 216)LW group (n = 216)
All postoperative complications (n, %)49 (20.5%)87 (27.6%)0.05944 (20.4%)52 (24.1%)0.418
 Anastomotic leakage6 (2.5%)10 (3.2%)0.8006 (2.8%)7 (3.2%)1.000
 Pancreatic fistula8 (3.4%)10 (3.2%)1.0006 (2.8%)7 (3.2%)1.000
 Intra-abdominal abscess6 (2.5%)14 (4.4%)0.2585 (2.3%)9 (4.2%)0.416
 Anastomotic stenosis3 (1.3%)5 (1.6%)1.0003 (1.4%)4 (1.9%)1.000
 Pneumonia5 (2.1%)23 (7.3%)0.0065 (2.3%)12 (5.6%)0.136
 Paralytic ileus5 (2.1%)2 (0.6%)0.1475 (2.3%)1 (0.5%)0.216
 Stasis syndrome6 (2.5%)4 (1.3%)0.3415 (2.3%)2 (0.9%)0.449
 Surgical site infection2 (0.8%)3 (1.0%)1.0002 (0.9%)3 (1.4%)1.000
 Urinary-tract infection2 (0.8%)3 (1.0%)1.0002 (0.9%)3 (1.4%)1.000
 Bacteremia2 (0.8%)8 (2.5%)0.2002 (0.9%)5 (2.3%)0.449
 Delirium6 (2.5%)10 (3.2%)0.8006 (2.8%)5 (2.3%)1.000
 Pleural effusion2 (0.8%)2 (0.6%)1.0002 (0.9%)1 (0.5%)1.000
 Heart failure4 (1.7%)8 (2.5%)0.5673 (1.4%)4 (1.9%)1.000
 Bleeding2 (0.8%)00.1862 (0.9%)00.499
 Enteritis1 (0.4%)3 (1.0%)0.6381 (0.5%)1 (0.5%)1.000
 Other3 (1.3%)7 (2.2%)0.5273 (1.4%)3 (1.4%)1.000
Comparison of postoperative complications between early and late weekday groups (EW and LW)

30-day mortality and in-hospital deaths

Considering all 554 patients, 30-day mortality and overall mortality rates were 0.4% (2 patients) and 0.7% (4 patients), respectively. One death within 30 days was caused by pneumonia, while the other resulted from invasive infection by Streptococcus pneumoniae. One later in-hospital death was caused by heart failure and the other by multiple myeloma. No in-hospital death was a consequence of intra-abdominal infection related or unrelated to anastomotic leakage. No difference between groups was evident in 30-day mortality or other in-hospital deaths between groups (none in the EW group vs. 0.9% in the LW group, P = 0.499).

Survival outcomes

The median observation period was 4.9 years (interquartile range, 3.0 to 6.8 years). Before propensity score matching, 5-year OS rates were 84.8% and 84.0% for the EW and LW groups (P = 0.736), while 5-year RFS rates were 80.7% and 78.9% for the EW and LW groups, respectively (P = 0.576). Figures 2 and 3 show Kaplan–Meier survival curves for EW and LW groups after propensity score matching. The 5-year OS rate was 86.0% and 86.2% for the EW and LW groups, respectively (P = 0.981; Fig. 2A). The HR was 1.01 (95% CI 0.62 to 1.62). Five-year RFS rates were 81.9% and 81.1% for the EW and LW groups, respectively (P = 0.835; Fig. 3A). The HR was 0.96 (95% CI 0.63 to 1.46). When patients were subdivided according to pathologic TNM stage, no significant differences were evident in OS (Fig. 2B–D) or RFS (Fig. 3B–D).
Fig. 2

Kaplan–Meier curves comparing EW and LW for overall survival after propensity score matching. a All patients, b pathologic stage I patients, c stage II patients, and d stage III patients

Fig. 3

Kaplan–Meier curves comparing EW and LW for recurrence-free survival after propensity score matching. a All patients, b pathologic stage I patients, c stage II patients, and d stage III patients

Kaplan–Meier curves comparing EW and LW for overall survival after propensity score matching. a All patients, b pathologic stage I patients, c stage II patients, and d stage III patients Kaplan–Meier curves comparing EW and LW for recurrence-free survival after propensity score matching. a All patients, b pathologic stage I patients, c stage II patients, and d stage III patients

Subgroup analysis between Monday and Friday surgery

Gastric cancer patients underwent surgery on Monday (n = 233) and Friday (n = 204) were included. After propensity score matching, 167 matched pairs were selected. No statistically significant differences in characteristics were present between Monday and Friday groups (Table 4). No statistically significant differences were present between these groups for short-tern postoperative outcomes or pathologic findings (Tables 5 and 6). In addition, no significant differences were evident in OS or RFS between cohorts pathologic TNM stages (Figs. 4 and 5).
Table 4

Comparison of Monday and Friday groups before and after propensity score matching

Patients undergoing surgery on Mon. and Fri. (n = 437)P valuePropensity score-matched patients (n = 334)P value
Mon. group (n = 233)Fri. group (n = 204)Mon. group (n = 167)Fri. group (n = 167)
Age, years (median, IQR)70 (62–77)69 (62–77)0.97870 (62–77)69 (62–77)0.855
Gender (n, %)1.0001.000
 Male155 (66.5)135 (66.2)110 (65.9)111 (66.5)
 Female78 (33.5)69 (33.8)57 (34.1)56 (33.5)
Time period (n, %)0.2440.181
 2004–2010104 (44.6)79 (38.7)61 (36.5)74 (44.3)
 2011–2017129 (55.4)125 (61.3)106 (63.5)93 (55.7)
BMI, kg/m2 (median, IQR)22.7 (20.9–24.5)22.5 (20.4–24.8)0.33322.6 (21.0–24.5)22.5 (20.7–25.0)0.935
Diabetes mellitus (n, %)0.8961.000
 Absent197 (84.6)171 (83.8)139 (83.2)140 (83.8)
 Present36 (15.4)33 (16.2)28 (16.8)27 (16.2)
COPD (n, %)1.0000.620
 Absent220 (94.4)192 (94.1)160 (95.8)157 (94.1)
 Present13 (5.6)12 (5.9)7 (4.2)10 (6.0)
Hemoglobin, g/dl (median, IQR)12.7 (11.7–13.9)1 2.7 (11.3–13.7)0.35812.6 (11.7–13.9)12.8 (11.6–13.9)0.848
Albumin, g/dl (median, IQR)4.1 (3.9–4.4)4.0 (3.7–4.3)0.0094.1 (3.8–4.3)4.1 (3.8–4.3)0.799
CEA, ng/ml (median, IQR)1.5 (0.9–2.5)1.6 (0.9–2.4)0.8291.5 (0.9–2.3)1.6 (0.9–2.5)0.920
CA19-9, U/ml (median, IQR)9.4 (6.0–15.3)9.4 (6.0–16.6)0.4829.4 (6.5–15.0)9.3 (6.0–16.0)0.608
Impairment of respiratory function (n, %)0.5430.907
 Absent152 (65.2)139 (68.1)114 (68.3)112 (67.1)
 Present81 (34.8)65 (31.9)53 (31.7)55 (32.9)
Clinical tumor depth (n, %)0.7630.720
 cT1124 (53.2)115 (56.4)94 (56.3)104 (62.3)
 cT253 (22.8)39 (19.1)36 (21.6)31 (18.6)
 cT333 (14.2)32 (15.7)23 (13.8)21 (12.6)
 cT423 (9.9)18 (8.8)14 (8.4)11 (6.6)
Clinical lymph node metastasis (n, %)0.6720.701
 cN0181 (77.7)215 (74.5)133 (79.6)136 (81.4)
 cN140 (17.2)72 (18.6)24 (14.4)24 (14.4)
 cN211 (4.7)25 (5.4)9 (5.4)5 (3.0)
 cN31 (0.4)3 (1.5)1 (0.6)2 (1.2)
Clinical TNM stage (n, %)0.4860.868
 I161 (69.1)141 (69.1)120 (71.9)126 (75.5)
 IIA16 (6.9)13 (6.4)10 (6.0)9 (5.4)
 IIB20 (8.6)11 (5.4)13 (7.8)10 (6.0)
 III36 (15.5)39 (19.1)24 (14.4)22 (13.2)
Operative procedure (n, %)0.6581.000
 Distal gastrectomy163 (70.0)148 (72.6)123 (73.7)122 (73.1)
 Proximal gastrectomy3 (1.3)1 (0.5)01 (0.6)
 Total gastrectomy67 (28.8)55 (27.0)44 (26.4)44 (26.4)
Operative approach (n, %)0.0990.909
 Open107 (45.9)77 (37.8)59 (35.3)61 (36.5)
 Laparoscopic126 (54.1)127 (62.3)108 (64.7)106 (63.5)
Lymph node dissection (n, %)0.9241.000
 D1/D1+122 (52.4)108 (52.9)96 (57.5)97 (58.1)
 D2 or more111 (47.6)96 (47.1)71 (42.5)70 (41.9)

Mon. Monday, Fri. Friday, BMI body mass index, COPD chronic obstructive pulmonary disease, IQR interquartile range, CEA carcinoembryonic antigen, CA carbohydrate antigen

Table 5

Comparison of postoperative outcomes and pathologic findings between Monday and Friday groups

Patients undergoing surgery on Mon. and Fri. (n = 437)P valuePropensity score-matched patients (n = 334)P value
Mon. group (n = 233)Fri. group (n = 204)Mon. group (n = 167)Fri. group (n = 167)
Operative time, minutes (median, IQR)350 (290–423)355 (300–430)0.458350 (290–420)355 (300–430)0.427
Operative blood loss, grams (median, IQR)212 (40–487)100 (20–433)0.059103 (20–357)100 (20–390)0.911
Blood transfusion (n, %)1.0000.199
 Not performed194 (83.3)170 (83.3)140 (83.8)149 (89.2)
 Performed39 (16.7)34 (16.7)27 (16.2)18 (10.8)
Hospital stay after surgery, days (median, IQR)13 (11–18)12 (10–17)0.05213 (10–18)12 (10–15)0.054
Death within 30 days after surgery (n, %)0 (0)2 (1.0)0.2170 (0)2 (1.2)0.499
In-hospital death (n, %)0 (0)3 (1.5)0.1010 (0)2 (1.2)0.499
Adjuvant chemotherapy (n, %)0.4380.651
 Absent198 (85.0)167 (81.9)139 (83.2)143 (85.6)
 Present35 (15.0)37 (18.1)28 (16.8)24 (14.4)
Tumor diameter, mm (median, IQR)35 (25–50)35 (20–60)0.45031 (22–50)32 (20–51)0.992
Retrieved number of lymph nodes (median, IQR)40 (27–50)39 (28–54)0.51440 (29–49)37 (26–53)0.986
Pathological tumor depth (n, %)0.2070.839
 pT1130 (55.8)110 (53.9)102 (61.1)99 (59.3)
 pT241 (17.6)28 (13.7)26 (15.6)25 (15.0)
 pT341 (17.6)35 (17.2)25 (15.0)24 (14.4)
 pT421 (9.0)31 (15.2)14 (8.4)19 (11.4)
Pathological lymph node metastasis (n, %)0.6340.520
 pN0170 (73.0)144 (70.6)122 (73.1)130 (77.8)
 pN126 (11.2)27 (13.2)20 (12.0)18 (10.8)
 pN210 (4.3)13 (6.4)9 (5.4)4 (2.4)
 pN327 (11.6)20 (9.8)16 (9.6)15 (9.0)
Pathological TNM stage (n, %)0.1180.999
 IA117 (50.2)104 (51.0)92 (55.1)93 (55.7)
 IB41 (17.6)26 (12.8)26 (15.6)26 (15.6)
 IIA24 (10.3)17 (8.3)14 (8.4)16 (9..6)
 IIB17 (7.3)20 (9.8)12 (7.2)10 (6.0)
 IIIA8 (3.4)19 (9.3)8 (4.8)8 (4.8)
 IIIB20 (8.6)12 (5.9)12 (7.2)11 (6.6)
 IIIC6 (2.6)6 (2.9)3 (1.8)3 (1.8)

Mon. Monday, Fri. Friday, IQR interquartile range

Table 6

Comparison of postoperative complications between Monday and Friday groups

Patients undergoing surgery on Mon. and Fri. (n = 437)P valuePropensity score-matched patients (n = 334)P value
Mon. group (n = 233)Fri. group (n = 204)Mon. group (n = 167)Fri. group (n = 167)
All postoperative complications: n (%)47 (20.2)53 (26.0)0.17135 (21.0)39 (23.4)0.693
 Anastomotic leakage5 (2.2)6 (2.9)0.7625 (3.0)5 (3.0)1.000
 Pancreatic fistula8 (3.4)5 (2.5)0.5876 (3.6)4 (2.4)0.750
 Intra-abdominal abscess6 (2.6)6 (2.9)1.0005 (3.0)4 (2.4)1.000
 Anastomotic stenosis3 (1.3)5 (2.5)0.4823 (1.8)4 (2.4)1.000
 Pneumonia5 (2.2)15 (7.4)0.0113 (1.8)9 (5.4)0.139
 Paralytic ileus5 (2.2)2 (1.0)0.4575 (3.0)1 (0.6)0.215
 Stasis syndrome6 (2.6)1 (0.5)0.1283 (1.8)00.248
 Surgical site infection2 (0.9)3 (1.5)0.6681 (0.6)3 (1.8)0.623
 Urinary-tract infection2 (0.9)2 (1.0)1.0002 (1.2)2 (1.2)1.000
 Bacteremia2 (0.9)3 (1.5)0.6681 (0.6)3 (1.8)0.623
 Delirium6 (2.6)9 (4.4)0.3075 (3.0)4 (2.4)1.000
 Pleural effusion2 (0.9)1 (0.5)1.0002 (1.2)1 (0.6)1.000
 Heart failure4 (1.7)3 (1.5)1.0002 (1.2)2 (1.2)1.000
 Bleeding2 (0.9)00.5012 (1.2)00.499
 Enteritis0000
 Other3 (1.3)3 (1.5)1.0002 (1.2)2 (1.2)1.000

Mon. Monday, Fri. Friday

Fig. 4

Kaplan–Meier curves comparing Monday and Friday for overall survival after propensity score matching. a All patients, b pathologic stage I patients, c stage II patients, and d stage III patients

Fig. 5

Kaplan–Meier curves comparing Monday and Friday for recurrence-free survival after propensity score matching. a All patients, b pathologic stage I patients, c stage II patients, and d stage III patients

Comparison of Monday and Friday groups before and after propensity score matching Mon. Monday, Fri. Friday, BMI body mass index, COPD chronic obstructive pulmonary disease, IQR interquartile range, CEA carcinoembryonic antigen, CA carbohydrate antigen Comparison of postoperative outcomes and pathologic findings between Monday and Friday groups Mon. Monday, Fri. Friday, IQR interquartile range Comparison of postoperative complications between Monday and Friday groups Mon. Monday, Fri. Friday Kaplan–Meier curves comparing Monday and Friday for overall survival after propensity score matching. a All patients, b pathologic stage I patients, c stage II patients, and d stage III patients Kaplan–Meier curves comparing Monday and Friday for recurrence-free survival after propensity score matching. a All patients, b pathologic stage I patients, c stage II patients, and d stage III patients

Discussion

Our results indicated absence of significant differences in postoperative complications and 30-day mortality between EW and LW groups. The LW group experienced OS and RFS similar to those for the EW group. A subgroup analysis comparing Monday with Friday surgery also showed similar results. To the best of our knowledge, the impact of operative timing within the week for gastrectomy to treat gastric cancer on short- and long-term outcomes according to propensity score matching analysis has not been reported previously. In this study, patients in the LW group had significantly lower serum albumin concentrations, greater tumor depth, and more advanced lymph node metastases. Similarly to our results, other studies have reported larger numbers of advanced cancer cases undergoing surgery later in the week [5, 11], but the reason for this is not clear. No significant difference was evident between our two groups concerning postoperative complications in general or 30-day mortality. However, our LW group showed a significantly higher incidence of postoperative pneumonia than EW group patients. Advanced gastric cancer and poor nutrition may have contributed to the development of pneumonia [12, 13]. After propensity score matching, no significant differences were evident between EW and LW groups either for postoperative complications including pneumonia or for 30-day mortality. Previous studies found that operative timing during the week when esophagectomy or gastrectomy was performed did not significantly influence risk of 30- or 90-day mortality, but details of postoperative complications were not given [6, 14, 15]. After we adjusted for variables including hypoalbuminemia and pathologic TNM stage, we found no significant difference between groups in incidence of any individual postoperative complication or in 30-day mortality. Previous studies have examined effects of day of the week when cancer surgery was performed on long-term outcomes [4, 16]. As for gastric cancer surgery, a recent study from the Netherlands found gastrectomy performed late in the week to be associated with a lower lymph node yield than gastrectomy early in the week [15]. However, conclusive evidence has not been found for significant impact of day of surgery on postoperative survival in patients undergoing gastrectomy for gastric cancer [14, 15]. In some reports nutritional status, surgical procedures, extent of lymph node dissection, postoperative complications, and pathologic stage, which often are associated with postoperative prognosis, were not described in detail. In our study these background factors were investigated thoroughly. Patients in the LW group had significantly lower serum albumin, greater tumor depth, and more advanced lymph node metastases than those in EW group. We therefore minimized effect of such background factors using propensity score matching between EW and the LW groups, after which we found no difference between groups, not only for number of lymph nodes dissected but also for long-term prognosis at any stage. A previous report used propensity score matching analysis to isolate the influence of day of surgery on subsequent mortality, finding excess mortality following Friday procedures [17]; however, that study concerned elective colorectal resections for inflammatory bowel disease and other non-oncologic indications as well as malignant disease. Our study is the first to demonstrate that after adjustment for confounding variables, long-term gastric cancer outcomes for patients at any disease stage after gastrectomy were not influenced by weekday of surgery. Our results demonstrated absence of a need to restrict surgery for gastric cancer to early weekdays. A surgeon may be better rested early in the work week than later because sleep deficits and fatigue could accrue as the week progresses. The contribution of physician fatigue to human error has become a major concern, and has led to enactment of work-hours limitations [18]. Studies using surgical simulation tools have associated sleep deprivation with increased technical errors [19, 20]. Further, previous studies found that a variety of surgical procedures performed on Friday were associated with higher 30-day mortality than similar surgery early in the week [21, 22]. However, our propensity-matched study demonstrated that early vs. late weekday surgery was not associated with differences in postoperative outcome after gastrectomy for gastric cancer. Two factors might explain this lack of a weekday effect. First, surgical indications and preoperative, operative, and postoperative procedures for gastric cancer patients are defined by standardized guidelines in Japan [8], which could help to maintain quality of perioperative management even when the surgeon is tired or the number of staff is reduced. Perioperative management and treatment for postoperative complications are less likely to be dependent on the day of the week. According to a nationwide Japanese database, 30-day mortality is low for both distal gastrectomy (0.6%) and total gastrectomy (1.0%) [23], and our findings are consistent with the results of that report. Second, surgeons in this study may have been similarly rested early and late in the week. At our hospital, we perform emergency surgery for acute abdomen and similar clinical situations as well as elective surgery for malignant disease throughout the week. Effects involving attending surgeons’ sleep time during the week may be lessened by surgeons taking turns during case assignment. Further investigation of the influence of sleep time on surgical care is warranted. Some limitations are evident in our present study. First, its retrospective nature and single-institutional setting may have biased the data. Second, our study excluded patients who received neoadjuvant chemotherapy. While neoadjuvant chemotherapy is considered standard treatment for gastric cancer patients in most Western countries according to several reports [24, 25], it is not recommended as the standard treatment under Japanese guidelines since its effectiveness remains to be fully proven in the Japanese population [8]. Furthermore, the drugs given and duration of chemotherapy have changed during the time interval applicable to patients considered for this study. Therefore, patients who received neoadjuvant chemotherapy were excluded. Third, the number of gastrectomies on Tuesdays and Thursdays was extremely small because of a need to coordinate operating room schedules with other surgical services. We conducted a subgroup comparison between Monday and Friday surgery to supplement the comparison between EW and LW groups. Here too, the subgroups showed absence of a weekday effect on short- and long-term oncologic outcomes of gastrectomy for gastric cancer. Fourth, although many background factors that might have affected short- and long-term postoperative outcomes were adjusted for by our propensity score matching process, unknown variables that we failed to consider as covariates may have affected our analysis.

Conclusion

The present study demonstrated that short- and long-term postoperative results for gastric cancer were not affected by the weekday when gastrectomy was performed, and operative scheduling for gastric cancer patients need not be limited to early weekdays.
  24 in total

1.  Influence of day of surgery on mortality following elective colorectal resections.

Authors:  R S Vohra; T Pinkney; F Evison; I Begaj; D Ray; D Alderson; D G Morton
Journal:  Br J Surg       Date:  2015-06-24       Impact factor: 6.939

Review 2.  A systematic review of sleep deprivation and technical skill in surgery.

Authors:  Dale F Whelehan; Cathleen A McCarrick; Paul F Ridgway
Journal:  Surgeon       Date:  2020-02-11       Impact factor: 2.392

3.  Putative risk factors for postoperative pneumonia which affects poor prognosis in patients with gastric cancer.

Authors:  Jun Kiuchi; Shuhei Komatsu; Daisuke Ichikawa; Toshiyuki Kosuga; Kazuma Okamoto; Hirotaka Konishi; Atsushi Shiozaki; Hitoshi Fujiwara; Tomoyo Yasuda; Eigo Otsuji
Journal:  Int J Clin Oncol       Date:  2016-05-12       Impact factor: 3.402

4.  Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001-2007).

Authors:  Hitoshi Katai; Takashi Ishikawa; Kohei Akazawa; Yoh Isobe; Isao Miyashiro; Ichiro Oda; Shunichi Tsujitani; Hiroyuki Ono; Satoshi Tanabe; Takeo Fukagawa; Souya Nunobe; Yoshihiro Kakeji; Atsushi Nashimoto
Journal:  Gastric Cancer       Date:  2017-04-17       Impact factor: 7.370

5.  Weekday of cancer surgery in relation to prognosis.

Authors:  J Lagergren; F Mattsson; P Lagergren
Journal:  Br J Surg       Date:  2017-08-31       Impact factor: 6.939

6.  Effect of sleep deprivation on the performance of simulated laparoscopic surgical skill.

Authors:  Brian J Eastridge; Elizabeth C Hamilton; Grant E O'Keefe; Robert V Rege; Rawson J Valentine; Daniel J Jones; Seifu Tesfay; Erwin R Thal
Journal:  Am J Surg       Date:  2003-08       Impact factor: 2.565

7.  Mortality after nonemergent major surgery performed on Friday versus Monday through Wednesday.

Authors:  Marc M Zare; Kamal M F Itani; Tracy L Schifftner; William G Henderson; Shukri F Khuri
Journal:  Ann Surg       Date:  2007-11       Impact factor: 12.969

8.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.

Authors:  Shinichi Sakuramoto; Mitsuru Sasako; Toshiharu Yamaguchi; Taira Kinoshita; Masashi Fujii; Atsushi Nashimoto; Hiroshi Furukawa; Toshifusa Nakajima; Yasuo Ohashi; Hiroshi Imamura; Masayuki Higashino; Yoshitaka Yamamura; Akira Kurita; Kuniyoshi Arai
Journal:  N Engl J Med       Date:  2007-11-01       Impact factor: 91.245

9.  Surgical outcomes of gastroenterological surgery in Japan: Report of the National Clinical Database 2011-2017.

Authors:  Hiroshi Hasegawa; Arata Takahashi; Yoshihiro Kakeji; Hideki Ueno; Susumu Eguchi; Itaru Endo; Akira Sasaki; Shuji Takiguchi; Hiroya Takeuchi; Masaji Hashimoto; Akihiko Horiguchi; Tadahiko Masaki; Shigeru Marubashi; Kazuhiro Yoshida; Hiroyuki Konno; Mitsukazu Gotoh; Hiroaki Miyata; Yasuyuki Seto
Journal:  Ann Gastroenterol Surg       Date:  2019-05-20

10.  Minimally Invasive Oncologic Upper Gastrointestinal Surgery can be Performed Safely on all Weekdays: A Nationwide Cohort Study.

Authors:  Daan M Voeten; Arthur K E Elfrink; Suzanne S Gisbertz; Jelle P Ruurda; Richard van Hillegersberg; Mark I van Berge Henegouwen
Journal:  World J Surg       Date:  2021-05-25       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.